Nautilus Biotechnology, Inc.

    Jurisdiction
    United States
    ISIN
    US63909J1088 (NAUT)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    6 / 7

    Profile

    Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. Read full profile

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€33.33M
    EBIT margin
    0.0%
    Net income
    -€56.03M
    Net margin
    0.0%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Murphy Matthew B. General Counsel +20K $0.64 +$12.80K

    Earnings Calls

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 300K $258.69K +50K Buy

    Earnings Calls

    Latest earnings call: April 30, 2024 (Q1 2024)

    Add to watchlist

    Notifications